Austrian Patent Office Upholds Lipitor Patent

Law360, New York (October 17, 2006, 12:00 AM EDT) -- Pfizer Inc. has won yet another battle in its war against Ranbaxy Laboratories over its generic version of blockbuster cholesterol drug Lipitor, after the Austrian Patent Office upheld Pfizer’s basic patent for the drug.

The APO ruled that Ranbaxy’s generic version would infringe Pfizer’s patents for atorvastatin, the active ingredient in Lipitor, which in Austria is sold under the name Sortis.

Pfizer said that it would continue to take action against Ranbaxy to prevent the launch of a generic version of Lipitor before the patents expire...
To view the full article, register now.